Compassionate Use of 3, 4-Diaminopyridine in Lambert Eaton Myasthenic Syndrome
Aims: Treatment of Lambert-Eaton Myasthenic Syndrome
Principal Investigator:
David Randall, DO
IRB approval number:  EH02-041
Funding source:  NorthShore University HealthSystem
Contact:
  Please call 847.657.5875 with questions regarding the study
Open to enrollment: Yes

An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS) and Downbeat Nystagmus
Aims: The primary objective of the study is to provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available. The secondary objective of the study is to assess the long-term safety of amifampridine.
Principal Investigator: Alexandru Barboi, MD
IRB Approval Number: EH16-121
Contact: Please call 847.570.4046 with questions regarding the study
Open to enrollment: Yes